Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

KJKelley JulianNTNatalia TovarRNRavi Narra

Discussion

Loading...

Member takes

Overview

Clinical trials demonstrate sustained remission with limited bispecific antibody therapy in refractory multiple myeloma, suggesting improved outcomes and immune reconstitution.

Key Points

  • Investigate the effects of limited-duration bispecific antibody therapy on remission in relapsed/refractory multiple myeloma.
  • Multinational study identifying patients from clinical trials or standard care receiving bispecific antibodies.
  • Patients discontinued treatment for reasons other than progression and remained in remission for at least 3 months.
  • Data collected on demographics, treatment responses, infections, and humoral immunity recovery.
  • After screening 720 patients, 78 were included; 72% received BCMA-targeted antibodies.
  • 2-year relapse-free survival was 67% overall, with some groups approaching 80%.
  • Most patients experienced humoral immune reconstitution and a decrease in infections post-treatment.

Cite This Study

Julian et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e01ahttps://doi.org/10.1182/blood-2025-5757
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How long is long enough? Outcomes with finite-duration bispecific antibody therapy in multiple myeloma.2026
  2. 2Longitudinal analysis of T-cell phenotype and function during bispecific antibody therapy2025
  3. 3Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials2025 · 12 citations
  4. 4Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients2025
  5. 5P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS2026